Gilead Stock Surges on HIV Drug Study Results | ORBITAL AFFAIRS

- Advertisement -

Gilead’s Lenacapavir Shows Promise in Preventing HIV Infection

Key Takeaways

  • A Phase 3 trial of Gilead’s injectable drug lenacapavir found it was 100% effective in preventing HIV infection in women.
  • Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants.
  • More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval.
  • Shares of Gilead surged Thursday following the news.

Gilead Sciences experienced a significant surge in its stock price on Thursday as the biotech firm announced promising results from a Phase 3 trial of its injectable drug lenacapavir. The trial revealed that lenacapavir was 100% effective in preventing HIV infection in women, marking a significant breakthrough in HIV prevention research.

- Advertisement -

The results were so compelling that the independent Data Monitoring Committee (DMC) recommended that Gilead end the blind phase of the study and offer lenacapavir to all participants. This recommendation speaks to the strength of the data and the potential impact of lenacapavir in preventing HIV transmission.

- Advertisement -

### Zero HIV Infections Among Women Who Took Gilead’s Lenacapavir

The Phase 3 trial conducted by Gilead found zero cases of HIV infection among the 2,134 women who received lenacapavir. In contrast, several cases of HIV infection were reported among those who took Gilead’s current HIV pills, Truvada and Descovy. Truvada was the first pre-exposure prophylaxis (PrEP) treatment approved by the Food and Drug Administration (FDA), making the effectiveness of lenacapavir even more remarkable.

### More Testing Needed Before Applying for FDA Approval

- Advertisement -

While the results from the trial are promising, Gilead must conduct additional testing before applying for FDA approval. The company plans to run another Phase 3 test of lenacapavir in men who have sex with men and other at-risk groups. These results are expected later this year or early next year and will be crucial in determining the drug’s overall efficacy and safety profile.

Dr. Linda-Gail Bekker, head of the Desmond Tutu HIV Center at the University of Cape Town, South Africa, and former president of the International AIDS Society, expressed optimism about lenacapavir’s potential impact on HIV prevention. She believes that lenacapavir could offer a critical new choice for HIV prevention that aligns with the needs of individuals who could benefit from PrEP worldwide.

Following the announcement of the trial results, Gilead’s stock price surged by 8.2% to $68.31 as of 3 p.m. ET on Thursday. Despite this positive development, Gilead Sciences has seen a decline of close to 16% in its stock value this year, reflecting broader market trends and investor sentiment.

![Gilead Stock Price Surge](×480/GILD_2024-06-20_15-06-11-f0bf9df7db5041e2a4abbccca3ce4128.png)

In conclusion, Gilead’s lenacapavir has shown great promise in preventing HIV infection, particularly among women. The company’s commitment to further testing and regulatory approval underscores its dedication to advancing HIV prevention strategies and improving public health outcomes. As additional data becomes available, stakeholders will closely monitor Gilead’s progress towards bringing this innovative drug to market and potentially transforming the landscape of HIV prevention efforts globally.

**Read the original article on [Investopedia](**

News Desk

- Advertisement -

Explore more

Doctor Jekyll: A Story Based on Strange Case of Dr. Jekyll & Mr. Hyde | ORBITAL AFFAIRS

Doctor Jekyll: A Story Based on Strange Case of Dr. Jekyll...

Doctor Jekyll  is a British gothic horror film that will be released in 2023 and will be directed by Joe Stephenson. The screenplay for...
Chipotle Stock Drops Ahead of 50-for-1 Split: Key Levels to Watch

Chipotle Stock Drops Ahead of 50-for-1 Split: Key Levels to Watch

The Impact of Chipotle's Stock Split on Investor Behavior Key Takeaways: Chipotle shares dropped more than 6% on Thursday, just days before...

S&P 500 Index Dips After Crossing 5,500 | ORBITAL AFFAIRS

The S&P 500 Dips as Tech Sector Declines On Thursday, June 20, 2024, the S&P 500 experienced a slight decline of 0.3% after briefly surpassing...

Trump Media Stock Falls as SEC Decision May Flood Market With...

Trump Media Stock Tumbles as SEC Decision Could Flood Market with New Shares Key Takeaways Trump Media shares tumbled Thursday after a decision from...

Honeywell Expands Defense Portfolio with $1.9B CAES Systems Purchase

Honeywell International Expands Defense Portfolio with $1.9 Billion Acquisition of CAES Systems Holdings Key Takeaways Honeywell International announced the $1.9 billion purchase of aerospace...
Dragon Ball Sparking! ZERO Release Date Revealed for Summer Game Fest 2024

Dragon Ball Sparking! ZERO Release Date Revealed for Summer Game Fest...

  What is the Release Date of DRAGON BALL: Sparking! ZERO Game? What is the Game Modes of DRAGON BALL: Sparking! ZERO Game? What...

‘Where Were Scenes of ‘Where the Crawdads Sing’ Filmed? | ORBITAL...

The production of “Where the Crawdads Sing” film has become the subject of masses on various social media platforms. After watching the film, they...
Young Sheldon Filming Locations | ORBITAL AFFAIRS

Young Sheldon Filming Locations | ORBITAL AFFAIRS

Young Sheldon is an American comedy television series created by Chuck Lorre and Steven Molaro, narrated by Jim Parsons, and based on the sitcom...